dazodalibep   Click here for help

GtoPdb Ligand ID: 13453

Synonyms: MEDI-4920 | MEDI4920 | VIB 4920 | VIB-4920 | VIB4920
Immunopharmacology Ligand
Compound class: Peptide
Comment: Dazodalibep (VIB4920, formerly MEDI4920) is a fusion protein that is designed to bind to and neutralise the biological actions of the CD40 ligand (CD40L) [2,4]. Structurally dazodalibep contains two tandem human Tn3 tenascin C modules (that bind CD40L [5]) linked to human serum albumin. Previous studies have demonstrated that anti-CD40L antibodies can cause thromboembolic adverse events that arise through antibody Fc-mediated cross-linking between FcγRIIa and CD40L on platelets. The dazodalibep Fc negative fusion protein approach was initiated to mitigate these platelet-related safety issues.
No information available.
Summary of Clinical Use Click here for help
Dazodalibep (VIB4920) is being developed as an novel immunomodulator for the treatment of autoimmune diseases [1,7].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06104124 A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity Phase 3 Interventional Amgen
NCT06245408 A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State Phase 3 Interventional Amgen
NCT04129164 A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome Phase 2 Interventional Amgen 6
NCT04163991 A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid Arthritis Phase 2 Interventional Viela Bio (acquired by Horizon Therapeutics) 3